<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438486</url>
  </required_header>
  <id_info>
    <org_study_id>2019-411</org_study_id>
    <nct_id>NCT04438486</nct_id>
  </id_info>
  <brief_title>Effects of Barley Green in Patients With Hyperuricemia</brief_title>
  <official_title>Effects of Barley Green in Patients With Hyperuricemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This experiment evaluates the effect of Barley Green in patients with hyperuricemia ， and
      explores the effect of Barley Green on metabolic indexes such as uric acid, blood lipids,
      blood glucose, free fatty acids。130 adult participants , age 18 to 65 years, will be
      randomized into one of the two arms. Arm A (control group) will receive dietary guidance. Arm
      B will receive dietary guidance and Barley Green.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uric acid level</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Dietary Supplement</condition>
  <arm_group>
    <arm_group_label>dietary advice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dietary advice+ Barely Green</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group A</intervention_name>
    <description>specific dietary advice for Hyperuricemia</description>
    <arm_group_label>dietary advice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Group B</intervention_name>
    <description>Barely Green（three times a day, 5g(10 tablets)） dietary advice for Hyperuricemia as Group A</description>
    <arm_group_label>dietary advice+ Barely Green</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18-65 years old those who are willing to accept assessment and sign informed consent.

        Under the normal purine diet, two fasting blood uric acid levels on different days:
        420umol/l &lt;blood uric acid &lt;540 umol/l (male), 360 umol/l &lt;blood uric acid &lt;540 umol/l
        (female)

        Exclusion Criteria:

        Patients currently receiving treatment for hyperuricemia； Suffering from diseases that
        affect the digestion and absorption(such as chronic diarrhea, constipation, severe
        gastrointestinal inflammation, active gastrointestinal ulcers, after gastrointestinal
        resection, cholecystitis/cholecystectomy, etc.)； Suffering from cardiovascular and
        cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors,
        anemia, mental illness and memory disorders, epilepsy and other diseases; At the same time
        receive other functional food nutrition support (plant active substances, health food);
        Patients with abnormal liver function (alanine aminotransferase or/and aspartate
        aminotransferase exceeds 3 times the upper limit of normal value); patients with abnormal
        renal function (serum creatinine exceeds the upper limit of normal value)； Suffering from
        infectious diseases such as active tuberculosis and AIDS; People who are severely allergic
        to the ingredients of research； During pregnancy or lactation; Patients with physical
        disabilities and clinicians think it is not suitable to participate in the study (for
        example, suffering from serious diseases not included in the discharge criteria)； Gouty
        arthritis attack ≥ 2 times; One episode of gouty arthritis with blood uric acid &gt;480
        umol/l, or any of the following: age &lt;40 years old, evidence of gout stone or urate
        deposition in the joint cavity, uric acid nephrolithiasis or renal impairment
        (GFR≤89ml/(min·1.73m2)), hypertension, impaired glucose tolerance or diabetes,
        dyslipidemia, obesity, coronary heart disease, stroke, cardiac insufficiency; Blood uric
        acid&gt;480 umol/l combined with any of the following: uric acid nephrolithiasis or renal
        impairment (GFR≤89ml/(min·1.73m2)), hypertension, impaired glucose tolerance or diabetes,
        dyslipidemia, obesity, Coronary heart disease, stroke, heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pianhong Zhang, MS</last_name>
    <phone>+86057187783852</phone>
    <email>zrlcyyzx@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoxu Huang, MS</last_name>
    <phone>+8618067961987</phone>
    <email>xiaoxuhuang0909@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pianhong Zhang, MD</last_name>
      <phone>+86 057187783852</phone>
      <email>zrlcyyzx@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

